Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02852837
What this trial is testing

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 50
Not applicableNo Longer AvailableNCT02368301
What this trial is testing

Expanded Access Treatment Protocol CA204-143

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb
Early research (Phase 1)Study completedNCT00346255
What this trial is testing

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
ImmunoGen, Inc. 37
Early research (Phase 1)Study completedNCT03143985
What this trial is testing

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Koen van Besien 18
Not applicableStudy completedNCT03389347
What this trial is testing

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 40
Testing effectiveness (Phase 2)Looking for participantsNCT06644443
What this trial is testing

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Shenzhen University General Hospital 10
Early research (Phase 1)Study completedNCT00664898
What this trial is testing

The Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 18
Testing effectiveness (Phase 2)Study completedNCT00429949
What this trial is testing

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

Who this might be right for
Relapsed, Refractory or Plateau Phase Multiple Myeloma
Washington University School of Medicine 21
Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Testing effectiveness (Phase 2)Ended earlyNCT00112723
What this trial is testing

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+25 more
National Cancer Institute (NCI) 46
Large-scale testing (Phase 3)Ended earlyNCT02576977
What this trial is testing

Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC 251
Early research (Phase 1)Looking for participantsNCT07369895
What this trial is testing

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
O&D BioTech Group CO., Limited 18
Testing effectiveness (Phase 2)Study completedNCT01615029
What this trial is testing

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT03314181
What this trial is testing

Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 156
Early research (Phase 1)Study completedNCT04280328
What this trial is testing

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Corvus Pharmaceuticals, Inc. 7
Large-scale testing (Phase 3)Study completedNCT01734928
What this trial is testing

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 559
Early research (Phase 1)Study completedNCT02240719
What this trial is testing

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Who this might be right for
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Grade 1 Follicular Lymphoma+5 more
University of California, Davis 20
Not applicableUnknownNCT05893693
What this trial is testing

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Relapsed and/or Refractory Multiple MyelomaPlasma Cell Leukemia in Relapse
Aibin Liang，MD，Ph.D. 12
Large-scale testing (Phase 3)Study completedNCT01311687
What this trial is testing

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Who this might be right for
Multiple Myeloma
Celgene 455
Very early researchNot Yet RecruitingNCT06298266
What this trial is testing

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital 15
Next Page